CalciMedica (CALC) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Trading Symbol	GRAY
Entity Registrant Name	GRAYBUG VISION, INC.
Entity Central Index Key	0001534133
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		21,319,635
Entity File Number	001-39538
Entity Tax Identification Number	45-2120079
Entity Address, Address Line One	203 Redwood Shores Parkway
Entity Address, Address Line Two	Suite 620
Entity Address, City or Town	Redwood City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94065
City Area Code	650
Local Phone Number	487-2800
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Former Address
Document Information [Line Items]
Entity Address, Address Line One	275 Shoreline Drive
Entity Address, Address Line Two	Suite 450
Entity Address, City or Town	Redwood City, CA
Entity Address, Postal Zip Code	94065

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 11,452	$ 33,418
Short-term investments	61,102	61,615
Prepaid expenses and other current assets	1,942	4,207
Total current assets	74,496	99,240
Property and equipment, net	2,113	1,946
Prepaid expenses and other non-current assets	29	608
Total assets	76,638	101,794
Current liabilities:
Accounts payable	2,066	2,513
Accrued research and development	264	1,356
Other current liabilities	2,160	3,128
Total current liabilities	4,490	6,997
Deferred rent, long-term portion	12	11
Total liabilities	4,502	7,008
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock
Common stock	2	2
Additional paid-in capital	232,641	228,155
Accumulated deficit	(160,513)	(133,367)
Accumulated other comprehensive income (loss)	6	(4)
Total stockholders’ equity	72,136	94,786
Total liabilities and stockholders’ equity	$ 76,638	$ 101,794

Condensed Statements of Operati

Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 4,021	$ 4,757	$ 14,635	$ 15,474
General and administrative	3,996	2,064	12,611	5,183
Total operating expenses	8,017	6,821	27,246	20,657
Loss from operations	(8,017)	(6,821)	(27,246)	(20,657)
Interest income	28	3	100	120
Change in fair value of preferred stock tranche obligation		2,102		2,158
Net loss	(7,989)	(4,716)	(27,146)	(18,379)
Cumulative dividends on convertible preferred stock		(2,396)		(7,189)
Net loss attributable to common stockholders	$ (7,989)	$ (7,112)	$ (27,146)	$ (25,568)
Net loss per common share—basic and diluted	$ (0.38)	$ (2.52)	$ (1.28)	$ (13.74)
Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted	21,287,498	2,818,349	21,153,185	1,861,229

Condensed Statements of Compreh

Condensed Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net loss	$ (7,989)	$ (4,716)	$ (27,146)	$ (18,379)
Unrealized gain (loss) on available-for-sale securities, net of tax			10	(3)
Comprehensive loss	$ (7,989)	$ (4,716)	$ (27,136)	$ (18,382)

Condensed Statements of Convert

Condensed Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Convertible Preferred Stock
Beginning Balance at Dec. 31, 2019	$ (102,954)		$ 2,879	$ (105,836)	$ 3
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2019						117,809,883
Temporary Equity, Beginning Balance at Dec. 31, 2019						$ 131,363
Beginning Balance, Shares at Dec. 31, 2019		1,371,467
Stock issued on exercise of stock options	11		11
Stock issued on exercise of stock options, Shares		5,446
Stock-based compensation expense	226		226
Net loss	(7,794)			(7,794)
Unrealized gain (loss) on available-for-sale securities, net of tax	(3)				(3)
Ending Balance at Mar. 31, 2020	(110,514)		3,116	(113,630)
Temporary Equity, Ending Balance, Shares at Mar. 31, 2020						117,809,883
Temporary Equity, Ending Balance at Mar. 31, 2020						$ 131,363
Ending Balance, Shares at Mar. 31, 2020		1,376,913
Beginning Balance at Dec. 31, 2019	(102,954)		2,879	(105,836)	3
Temporary Equity, Beginning Balance, Shares at Dec. 31, 2019						117,809,883
Temporary Equity, Beginning Balance at Dec. 31, 2019						$ 131,363
Beginning Balance, Shares at Dec. 31, 2019		1,371,467
Net loss	(18,379)
Unrealized gain (loss) on available-for-sale securities, net of tax	(3)
Ending Balance at Sep. 30, 2020	90,634	$ 2	214,847	(124,215)
Ending Balance, Shares at Sep. 30, 2020		20,135,515
Beginning Balance at Mar. 31, 2020	(110,514)		3,116	(113,630)
Temporary Equity, Beginning Balance, Shares at Mar. 31, 2020						117,809,883
Temporary Equity, Beginning Balance at Mar. 31, 2020						$ 131,363
Beginning Balance, Shares at Mar. 31, 2020		1,376,913
Stock issued on exercise of stock options	12		12
Stock issued on exercise of stock options, Shares		5,287
Stock-based compensation expense	214		214
Net loss	(5,869)			(5,869)
Ending Balance at Jun. 30, 2020	(116,157)		3,342	(119,499)
Temporary Equity, Ending Balance, Shares at Jun. 30, 2020						117,809,883
Temporary Equity, Ending Balance at Jun. 30, 2020						$ 131,363
Ending Balance, Shares at Jun. 30, 2020		1,382,200
Issuance of common stock upon the initial public offering, net	79,529	$ 1	79,528
Issuance of common stock upon initial public offering, net of issuance costs, Shares		5,625,000
Conversion of convertible preferred stock into common stock upon the initial public offering	131,363	$ 1	131,362
Temporary Equity, Conversion of convertible preferred stock into common stock upon initial public offering, Shares						(117,809,883)
Temporary Equity, Conversion of convertible preferred stock into common stock upon initial public offering						$ (131,363)
Conversion of convertible preferred stock into common stock upon the initial public offering, Shares		13,085,913
Stock issued on exercise of stock options	54		54
Stock issued on exercise of stock options, Shares		42,402
Stock-based compensation expense	561		561
Net loss	(4,716)			(4,716)
Ending Balance at Sep. 30, 2020	90,634	$ 2	214,847	(124,215)
Ending Balance, Shares at Sep. 30, 2020		20,135,515
Beginning Balance at Dec. 31, 2020	94,786	$ 2	228,155	(133,367)	(4)
Beginning Balance, Shares at Dec. 31, 2020		20,979,265
Stock issued on exercise of stock options	92		92
Stock issued on exercise of stock options, Shares		76,679
Stock-based compensation expense	1,129		1,129
Net loss	(11,449)			(11,449)
Unrealized gain (loss) on available-for-sale securities, net of tax	4				4
Ending Balance at Mar. 31, 2021	84,562	$ 2	229,376	(144,816)
Ending Balance, Shares at Mar. 31, 2021		21,055,944
Beginning Balance at Dec. 31, 2020	94,786	$ 2	228,155	(133,367)	(4)
Beginning Balance, Shares at Dec. 31, 2020		20,979,265
Net loss	(27,146)
Unrealized gain (loss) on available-for-sale securities, net of tax	10
Ending Balance at Sep. 30, 2021	72,136	$ 2	232,641	(160,513)	6
Ending Balance, Shares at Sep. 30, 2021		21,316,591
Beginning Balance at Mar. 31, 2021	84,562	$ 2	229,376	(144,816)
Beginning Balance, Shares at Mar. 31, 2021		21,055,944
Stock issued on exercise of stock options	495		495
Stock issued on exercise of stock options, Shares		228,732
Stock-based compensation expense	1,312		1,312
Net loss	(7,708)			(7,708)
Unrealized gain (loss) on available-for-sale securities, net of tax	6				6
Ending Balance at Jun. 30, 2021	78,667	$ 2	231,183	(152,524)	6
Ending Balance, Shares at Jun. 30, 2021		21,284,676
Stock issued on exercise of stock options	27		27
Stock issued on exercise of stock options, Shares		11,915
Issuance of common stock upon vesting of restricted stock units, Shares		20,000
Stock-based compensation expense	1,431		1,431
Net loss	(7,989)			(7,989)
Ending Balance at Sep. 30, 2021	$ 72,136	$ 2	$ 232,641	$ (160,513)	$ 6
Ending Balance, Shares at Sep. 30, 2021		21,316,591

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net loss	$ (27,146)	$ (18,379)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	3,872	1,001
Depreciation	383	284
Change in fair value of preferred stock tranche obligation		(2,158)
Accretion of premium and discounts on investments, net	74	(17)
Changes in operating assets and liabilities:
Prepaid expenses and other current and non-current assets	2,844	227
Accounts payable	(513)	(1,204)
Accrued research and development	(1,092)	(1,310)
Other current and non-current liabilities	(968)	(747)
Deferred rent, long term portion	1	10
Net cash used in operating activities	(22,545)	(22,293)
Investing activities:
Purchases of property and equipment	(484)	(197)
Purchases of investments	(72,610)
Maturity of investments	73,059	20,100
Net cash (used in) provided by investing activities	(35)	19,903
Financing activities:
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts and commissions.		83,700
Proceeds from exercise of stock options	614	77
Payment of offering costs		(2,289)
Net cash provided by financing activities	614	81,488
Net (decrease) increase in cash and cash equivalents	(21,966)	79,098
Cash and cash equivalents at beginning of period	33,418	15,870
Cash and cash equivalents at end of period	11,452	94,968
Supplemental disclosures of non-cash investing and financing activities:
Deferred offering costs included in accounts payable and other current liabilities		1,837
Conversion of convertible preferred stock into common stock upon initial public offering		131,363
Property and equipment purchases included in accounts payable and other current liabilities	$ 115	$ 60

Organization

Organization	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization	1. Organization Graybug Vision, Inc., the Company or Graybug, is a clinical-stage biopharmaceutical company developing medicines for the treatment of diseases of the retina and optic nerve. The Company presently devotes substantially all of its resources to conducting research and development and raising capital. The Company was founded in May 2011 and maintains facilities in Redwood City, California and Baltimore, Maryland. The Company is subject to risks common to clinical stage companies in the biopharmaceutical industry, including dependence on the clinical success of its product candidates, ability to obtain regulatory approvals of its product candidates, compliance with regulatory requirements, the need for substantial additional financing and protection of its proprietary technology. Going Concern Considerations The Company incurred losses from operations and had negative cash flows from operating activities for the three and nine months ended September 30, 2021, and the Company’s accumulated deficit at September 30, 2021 was $160.5 million. The Company’s current operating plan indicates it will continue to incur losses from operations and generate negative cash flows from operating activities given expected ongoing expenditures related to research and development and the Company’s lack of revenue-generating activities at this point in the Company’s life cycle. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. In March 2021, the Company decided not to proceed with the significant investment required to initiate two Phase 3 clinical trials for GB-102 in late 2021. As a result, management continues to believe that the Company’s current cash, cash equivalents and short-term investments are adequate to meet its cash needs for at least 12 months from the issuance date of this Form 10-Q. The Company will seek to raise additional funds in order to further advance its research and development programs other than GB-102, operate its business, secure research and development collaborations, and meet its obligations as they come due. The Company is pursuing financing alternatives, similar to what the Company has previously executed, which include equity financing. Such sources of capital may not, however, be available to the Company in the necessary time frame, in the amounts that the Company requires, on terms that are acceptable to the Company, or at all. If the Company is unable to raise the necessary funds when needed or reduce spending on currently planned activities, it may not be able to continue the development of its products or the Company could be required to delay, scale back, or eliminate some or all of its research and development programs and other operations, which may materially harm its business, financial position and results of operations. COVID-19 Pandemic The impact of the worldwide spread of a novel strain of coronavirus (“COVID-19”) has been unprecedented and unpredictable,

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements contained in this Quarterly Report on Form 10-Q have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission, or SEC, and, therefore, certain information and disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, have been omitted. In the opinion of management, the information reflects all adjustments necessary to make the results of operations for the interim periods a fair statement of such operations. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for the full year. The condensed balance sheet at December 31, 2020 has been derived from the audited financial statements at that date, but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 5, 2021. Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to accrued research and development expenses, other long-lived assets, stock-based compensation and the valuation of deferred tax assets. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources, and adjusts those estimates and assumptions when facts and circumstances dictate. Related Party Transactions In August 2019, the Company engaged a consulting firm managed by the then-acting chief financial officer of the Company for professional services related to finance and other administrative functions. For the three and nine months ended September 30, 2020, the costs incurred under this arrangement totaled $212,000 and $657,000, respectively. These costs were recorded as general and administrative expense in the accompanying condensed statements of operations. The Company terminated its relationship with this entity in September 2020.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. • Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Current assets: Cash equivalents: Money market funds $ 8,133 — — $ 8,133 Total cash equivalents 8,133 — — 8,133 Short-term investments: Corporate debt securities — 1,123 — 1,123 Commercial paper — 56,478 — 56,478 U.S. Treasury notes — 3,501 — 3,501 Total short-term investments — 61,102 — 61,102 Total assets measured at fair value $ 8,133 $ 61,102 $ — $ 69,235 December 31, 2020 Level 1 Level 2 Level 3 Total Current assets: Cash equivalents: Money market funds $ 15,677 $ — $ — $ 15,677 Corporate debt securities — 2,500 — 2,500 Commercial paper — 13,499 — 13,499 Total cash equivalents 15,677 15,999 — 31,676 Short-term investments: Corporate debt securities — 11,588 — 11,588 Commercial paper — 50,027 — 50,027 Total short-term investments — 61,615 — 61,615 Total assets measured at fair value $ 15,677 $ 77,614 $ — $ 93,291 The following tables present information as to cost, unrealized gains and losses and fair value determination of the Company’s financial assets measured at fair value on a recurring basis (in thousands): September 30, 2021 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value Current assets: Cash equivalents: Money market funds $ 8,133 $ — $ — $ 8,133 Total cash equivalents 8,133 — — 8,133 Short-term investments: Corporate debt securities 1,123 — — 1,123 Commercial paper 56,472 6 — 56,478 U.S. Treasury notes 3,501 — — 3,501 Total short-term investments 61,096 6 — 61,102 Total assets measured at fair value $ 69,229 $ 6 $ — $ 69,235 December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value Current assets: Cash equivalents: Money market funds $ 15,677 $ — $ — $ 15,677 Corporate debt securities 2,502 — (2 ) 2,500 Commercial paper 13,498 1 — 13,499 Total cash equivalents 31,677 1 (2 ) 31,676 Short-term investments: Corporate debt securities 11,588 1 (1 ) 11,588 Commercial paper 50,030 2 (5 ) 50,027 Total short-term investments 61,618 3 (6 ) 61,615 Total assets measured at fair value $ 93,295 $ 4 $ (8 ) $ 93,291 Money market funds are highly liquid investments which are actively traded. The pricing information on the Company’s money market funds are based on quoted prices in active markets for identical securities. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. The fair value of investments is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. The pricing services utilize industry-standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities; issuer credit spreads; benchmark securities; prepayment/default projections based on historical data; and other observable inputs. This approach results in the classification of these securities as Level 2 of the fair value hierarchy. As of September 30, 2021, the contractual maturities of all available-for-sale investments were less than 12 months. There were no transfers between Levels 1, 2 or 3 for the periods presented.

Balance Sheet Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Components	4. Balance Sheet Components Other Current Liabilities Other current liabilities consisted of the following (in thousands): September 30, 2021 December 31, 2020 Salaries and benefits $ 1,465 $ 2,302 Professional services 344 425 Deferred rent 5 27 Other 346 374 Total other current liabilities $ 2,160 $ 3,128

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	5. Commitments and Contingencies The Company enters into contracts in the normal course of business with contract research organizations, or CROs, for clinical trials and contract manufacturing organizations, or CMOs, for clinical supply manufacturing and with vendors for equipment, preclinical research studies, research supplies and other services and products for operating purposes. Operating Lease Agreements The Company leases a facility in Baltimore, Maryland under an operating lease with a term through June 2023. Rent expense for the three months ended September 30, 2021 and 2020 was $175,000 and $192,000, respectively. Rent expense for the nine months ended September 30, 2021 and 2020 was $553,000 and $544,000, respectively. On July 29, 2021, the Company entered into a lease agreement for approximately 2,560 rentable square feet of office space in Redwood City, California. The lease commenced on August 18, 2021 with a 12-month initial term expiring on August 31, 2022. This new facility replaced the Company’s existing Redwood City lease when it expired on August 31, 2021. Upon execution of the lease, the Company delivered to the lessor a sum of $31,000, consisting of a security deposit and one month's rent. The total lease obligation over the term of the lease will be approximately $186,000. Future minimum lease payments under the Company’s non–cancelable operating leases as of September 30, 2021 were as follows (in thousands): Year ended December 31: 2021 (remaining three months) $ 146 2022 527 2023 205 Total future minimum lease payments $ 878 Guarantees and Indemnifications In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2021 , the Company did not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.

Preferred Stock Tranche Obligat

Preferred Stock Tranche Obligation	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Preferred Stock Tranche Obligation	6. Preferred Stock Tranche Obligation In July 2019, the Company authorized the sale of up to 61,773,000 shares of its Series C Convertible Preferred Stock, or Series C, at a price of $1.4693 per share, or Series C Financing. In July and August 2019, the Company issued 37,432,787 shares of Series C for aggregate gross proceeds of $55.0 million. In connection with this financing, certain purchasers of the Series C had the option to purchase up to an additional 17,014,902 shares of Series C at a price per share of $1.4693 for a period of up to 30 days after the Company notified them of the three-month readout from the Phase 2a clinical trial of GB-102 in patients with macular edema secondary to diabetic macular edema and retinal vein occlusion, or the Preferred Stock Tranche Obligation. The Company concluded that the Preferred Stock Tranche Obligation met the definition of a freestanding financial instrument, as the rights were legally detachable and separately exercisable from the Series C. Therefore, the Company allocated the proceeds received from the issuance of shares under the Series C Preferred Stock Purchase Agreement between the Preferred Stock Tranche Obligation and the Series C. The fair value of the Preferred Stock Tranche Obligation of $2.2 million on issuance was allocated from the $55.0 million proceeds of the Series C Financing and classified as a current liability on the balance sheet as the Series C would become redeemable upon a deemed liquidation event, the occurrence of which was not within the Company’s control. In September 2020, the board of directors and the Series C investors amended the Series C stock purchase agreement such that the Preferred Stock Tranche Obligation was no longer exercisable and expired upon the effectiveness of the Company’s IPO registration statement. As a result, the liability for the Preferred Stock Tranche Obligation was permanently eliminated as of September 24, 2020. Due to the low probability of the Preferred Stock Tranche Obligation being settled, the fair value immediately prior to the IPO was immaterial.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation 2020 Equity Incentive Plan In August 2020, the Company’s board of directors and stockholders adopted the Company’s 2020 Equity Incentive Plan, or the 2020 Plan, that became effective in connection with the IPO , and serves as the successor to the Company’s 2015 Stock Incentive Plan, or the 2015 Plan. The Company’s 2020 Plan authorizes the award of stock options, restricted stock units, or RSUs, restricted stock awards, or RSAs, stock appreciation rights, or SARs, performance awards and stock bonus awards. On January 1, 2021, the aggregate number of shares reserved for issuance was increased by an additional 1,048,963 shares pursuant to the automatic share reserve increase provision of the 2020 Plan. 2020 Employee Stock Purchase Plan In August 2020 the Company’s board of directors and stockholders adopted the Company’s 2020 Employee Stock Purchase Plan, or the ESPP, that became effective in connection with the IPO Stock-Based Compensation Expense Stock-based compensation expense recognized for options and RSUs granted was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 321 $ 105 $ 912 $ 245 General and administrative 1,110 456 2,960 756 Total stock-based compensation expense $ 1,431 $ 561 $ 3,872 $ 1,001 As of September 30, 2021, the total unrecognized stock-based compensation expense related to outstanding unvested stock awards that are expected to vest was $16.9 million, which the Company expects to recognize over an estimated weighted-average term of 3.1 years.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The Company did not record a provision or benefit for income taxes during the three and nine months ended September 30, 2021 and 2020. As of both September 30, 2021 and 2020, and consistent with all prior periods, the Company continued to maintain a full valuation allowance against all of its deferred tax assets in light of its history of cumulative net losses.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	9. Net Loss Per Share Attributable to Common Stockholders The Company calculates basic net loss per share based on the weighted-average number of common shares outstanding during the periods presented and calculates diluted net loss per share based on the weighted-average number of shares of common stock outstanding, including potentially dilutive securities. For the three and nine month period ended September 30, 2020, the Company’s net loss available to common stockholders included the cumulative dividends on convertible preferred stock of $2.4 million and $7.2 million, respectively. For the three and nine months ended September 30, 2021 and 2020, basic and diluted net loss per share are the same due to the Company’s net losses and the requirement to exclude potentially dilutive securities which would have an antidilutive effect on net loss per share. During the three and nine months ended September 30, 2021 and 2020, potentially dilutive securities consisted of the common shares underlying outstanding stock options, warrants, and RSUs. The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: As of September 30, 2021 2020 Stock options to purchase common stock 3,815,682 2,615,892 Restricted stock units 984,700 80,000 Warrants to purchase common stock 27,759 27,759 Under the Series C Financing, up to an additional 17,014,902 shares of convertible preferred stock could have been contingently issued upon achievement of certain development milestones. However, in September 2020, the board of directors and the Series C investors amended the Series C stock purchase agreement such that the Preferred Stock Tranche Obligation was no longer exercisable and expired upon the effectiveness of the Company’s IPO registration statement.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed financial statements contained in this Quarterly Report on Form 10-Q have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission, or SEC, and, therefore, certain information and disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, have been omitted. In the opinion of management, the information reflects all adjustments necessary to make the results of operations for the interim periods a fair statement of such operations. All such adjustments are of a normal recurring nature. Interim results are not necessarily indicative of results for the full year. The condensed balance sheet at December 31, 2020 has been derived from the audited financial statements at that date, but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements included in the Annual Report on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 5, 2021.
Use of Estimates	Use of Estimates The preparation of condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to accrued research and development expenses, other long-lived assets, stock-based compensation and the valuation of deferred tax assets. The Company bases its estimates using historical experience, Company forecasts and future plans, current economic conditions, and information from third-party professionals that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources, and adjusts those estimates and assumptions when facts and circumstances dictate.
Related Party Transactions	Related Party Transactions In August 2019, the Company engaged a consulting firm managed by the then-acting chief financial officer of the Company for professional services related to finance and other administrative functions. For the three and nine months ended September 30, 2020, the costs incurred under this arrangement totaled $212,000 and $657,000, respectively. These costs were recorded as general and administrative expense in the accompanying condensed statements of operations. The Company terminated its relationship with this entity in September 2020.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Assets Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): September 30, 2021 Level 1 Level 2 Level 3 Total Current assets: Cash equivalents: Money market funds $ 8,133 — — $ 8,133 Total cash equivalents 8,133 — — 8,133 Short-term investments: Corporate debt securities — 1,123 — 1,123 Commercial paper — 56,478 — 56,478 U.S. Treasury notes — 3,501 — 3,501 Total short-term investments — 61,102 — 61,102 Total assets measured at fair value $ 8,133 $ 61,102 $ — $ 69,235 December 31, 2020 Level 1 Level 2 Level 3 Total Current assets: Cash equivalents: Money market funds $ 15,677 $ — $ — $ 15,677 Corporate debt securities — 2,500 — 2,500 Commercial paper — 13,499 — 13,499 Total cash equivalents 15,677 15,999 — 31,676 Short-term investments: Corporate debt securities — 11,588 — 11,588 Commercial paper — 50,027 — 50,027 Total short-term investments — 61,615 — 61,615 Total assets measured at fair value $ 15,677 $ 77,614 $ — $ 93,291
Summary of Company's Financial Assets Measured at Fair Value	The following tables present information as to cost, unrealized gains and losses and fair value determination of the Company’s financial assets measured at fair value on a recurring basis (in thousands): September 30, 2021 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value Current assets: Cash equivalents: Money market funds $ 8,133 $ — $ — $ 8,133 Total cash equivalents 8,133 — — 8,133 Short-term investments: Corporate debt securities 1,123 — — 1,123 Commercial paper 56,472 6 — 56,478 U.S. Treasury notes 3,501 — — 3,501 Total short-term investments 61,096 6 — 61,102 Total assets measured at fair value $ 69,229 $ 6 $ — $ 69,235 December 31, 2020 Amortized Cost Unrealized Gains Unrealized Losses Aggregate Fair Value Current assets: Cash equivalents: Money market funds $ 15,677 $ — $ — $ 15,677 Corporate debt securities 2,502 — (2 ) 2,500 Commercial paper 13,498 1 — 13,499 Total cash equivalents 31,677 1 (2 ) 31,676 Short-term investments: Corporate debt securities 11,588 1 (1 ) 11,588 Commercial paper 50,030 2 (5 ) 50,027 Total short-term investments 61,618 3 (6 ) 61,615 Total assets measured at fair value $ 93,295 $ 4 $ (8 ) $ 93,291

Balance Sheet Components (Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2021
Balance Sheet Related Disclosures [Abstract]
Schedule of Other Current Liabilities	Other current liabilities consisted of the following (in thousands): September 30, 2021 December 31, 2020 Salaries and benefits $ 1,465 $ 2,302 Professional services 344 425 Deferred rent 5 27 Other 346 374 Total other current liabilities $ 2,160 $ 3,128

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments under the Company’s non–cancelable operating leases as of September 30, 2021 were as follows (in thousands): Year ended December 31: 2021 (remaining three months) $ 146 2022 527 2023 205 Total future minimum lease payments $ 878

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted	Stock-based compensation expense recognized for options and RSUs granted was as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 321 $ 105 $ 912 $ 245 General and administrative 1,110 456 2,960 756 Total stock-based compensation expense $ 1,431 $ 561 $ 3,872 $ 1,001

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following outstanding potentially dilutive shares have been excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: As of September 30, 2021 2020 Stock options to purchase common stock 3,815,682 2,615,892 Restricted stock units 984,700 80,000 Warrants to purchase common stock 27,759 27,759

Organization - Additional Infor

Organization - Additional Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accumulated deficit	$ 160,513	$ 133,367

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
General and Administrative
Summary of Significant Accounting Policies [Line Items]
Related party transaction, costs incurred	$ 212,000	$ 657,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash equivalents	$ 8,133	$ 31,676
Short-term investments	61,102	61,615
Assets measured at fair value	69,235	93,291
Money Market Funds
Current assets:
Cash equivalents	8,133	15,677
Level 1
Current assets:
Cash equivalents	8,133	15,677
Assets measured at fair value	8,133	15,677
Level 1 | Money Market Funds
Current assets:
Cash equivalents	8,133	15,677
Level 2
Current assets:
Cash equivalents		15,999
Short-term investments	61,102	61,615
Assets measured at fair value	61,102	77,614
Corporate Debt Securities
Current assets:
Cash equivalents		2,500
Short-term investments	1,123	11,588
Corporate Debt Securities | Level 2
Current assets:
Cash equivalents		2,500
Short-term investments	1,123	11,588
Commercial Paper
Current assets:
Cash equivalents		13,499
Short-term investments	56,478	50,027
Commercial Paper | Level 2
Current assets:
Cash equivalents		13,499
Short-term investments	56,478	$ 50,027
U.S. Treasury Notes
Current assets:
Short-term investments	3,501
U.S. Treasury Notes | Level 2
Current assets:
Short-term investments	$ 3,501

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Company 's Financial Assets Measured at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total cash equivalents, Aggregate Fair Value	$ 8,133	$ 31,676
Total short-term investments, Aggregate Fair Value	61,102	61,615
Total asset measured at fair value, Aggregate Fair Value	69,235	93,291
Fair Value, Recurring
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total cash equivalents, Amortized Cost	8,133	31,677
Total cash equivalents, Unrealized Gains		1
Total cash equivalents, Unrealized Losses		(2)
Total cash equivalents, Aggregate Fair Value	8,133	31,676
Total short-term investments, Amortized Cost	61,096	61,618
Total short-term investments, Unrealized Gains	6	3
Total short-term investments, Unrealized Losses		(6)
Total short-term investments, Aggregate Fair Value	61,102	61,615
Total asset measured at fair value, Amortized Cost	69,229	93,295
Total asset measured at fair value, Unrealized Gains	6	4
Total asset measured at fair value, Unrealized Losses		(8)
Total asset measured at fair value, Aggregate Fair Value	69,235	93,291
Fair Value, Recurring | Money Market Funds
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total cash equivalents, Amortized Cost	8,133	15,677
Total cash equivalents, Aggregate Fair Value	8,133	15,677
Fair Value, Recurring | Corporate Debt Securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total cash equivalents, Amortized Cost		2,502
Total cash equivalents, Unrealized Losses		(2)
Total cash equivalents, Aggregate Fair Value		2,500
Total short-term investments, Amortized Cost	1,123	11,588
Total short-term investments, Unrealized Gains		1
Total short-term investments, Unrealized Losses		(1)
Total short-term investments, Aggregate Fair Value	1,123	11,588
Fair Value, Recurring | Commercial Paper
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total cash equivalents, Amortized Cost		13,498
Total cash equivalents, Unrealized Gains		1
Total cash equivalents, Aggregate Fair Value		13,499
Total short-term investments, Amortized Cost	56,472	50,030
Total short-term investments, Unrealized Gains	6	2
Total short-term investments, Unrealized Losses		(5)
Total short-term investments, Aggregate Fair Value	56,478	$ 50,027
Fair Value, Recurring | U.S. Treasury Notes
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total short-term investments, Amortized Cost	3,501
Total short-term investments, Aggregate Fair Value	$ 3,501

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Other-than-temporary impairment losses	$ 0	$ 0
Fair value assets, level 1 to level 2 transfers, amount	0
Fair value assets, level 2 to level 1 transfers, amount	0
Fair value assets, transfers into level 3	0
Fair value liabilities, level 1 to Level 2 transfers amount	0
Fair value liabilities, level 2 to Level 1 transfers amount	0
Fair value liabilities, transfers into level 3	$ 0

Balance Sheet Components - Sche

Balance Sheet Components - Schedule of Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Other Liabilities Current [Abstract]
Salaries and benefits	$ 1,465	$ 2,302
Professional services	344	425
Deferred rent	5	27
Other	346	374
Total other current liabilities	$ 2,160	$ 3,128

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details)	Jul. 29, 2021USD ($)ft²	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Loss Contingencies [Line Items]
Unpaid cancellation and other related costs				$ 0
Contract termination commitment						$ 3,700,000
Rent expense		$ 175,000	$ 192,000	$ 553,000	$ 544,000
Baltimore, Maryland
Loss Contingencies [Line Items]
Operating lease, term				2023-06
Redwood City, California
Loss Contingencies [Line Items]
Area of office space | ft²	2,560
Lessee operating lease commencement date	Aug. 18, 2021
Lessee, operating lease, term of contract	12 months
Lessee operating lease expiration date	Aug. 31, 2022			Aug. 31, 2021
Total lease obligation over the term of the lease	$ 186,000
Payment of security deposit and rent upon execution of lease	$ 31,000
General and Administrative
Loss Contingencies [Line Items]
Commitment expenses recognized				$ 2,200,000
Research and Development
Loss Contingencies [Line Items]
Contractual obligation		1,100,000		$ 1,100,000
Research and Development | Minimum
Loss Contingencies [Line Items]
Contractual obligation term				3 months
Research and Development | Maximum
Loss Contingencies [Line Items]
Contractual obligation term				18 months
Fixed Asset Purchase Agreements
Loss Contingencies [Line Items]
Write off of deposits				$ 1,300,000
Cancellation costs not yet been paid		$ 900,000		$ 900,000

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Sep. 30, 2021USD ($)
Commitments And Contingencies Disclosure [Abstract]
2021 (remaining three months)	$ 146
2022	527
2023	205
Total future minimum lease payments	$ 878

Preferred Stock - Additional In

Preferred Stock - Additional Information (Details) - Series C Convertible Preferred Stock - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	2 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2019	Aug. 31, 2019	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Temporary Equity [Line Items]
Convertible preferred stock authorized to sell	61,773,000
Convertible preferred stock, price per share	$ 1.4693
Convertible preferred stock, shares issued		37,432,787
Gross proceeds from issue of convertible preferred stock		$ 55
Convertible preferred stock, price per share	$ 1.4693
Gain on change in fair value of preferred stock tranche obligation			$ 2.1		$ 2.2
Current Liability
Temporary Equity [Line Items]
Fair value of preferred stock tranche obligation	$ 2.2
Maximum
Temporary Equity [Line Items]
Convertible preferred stock option to purchase additional shares	17,014,902			17,014,902
Convertible preferred stock option to purchase additional shares after notified, period	30 days

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Jan. 01, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards	$ 16.9
Total unrecognized stock-based compensation expenses related to outstanding unvested stock awards weighted-average term of recognition	3 years 1 month 6 days
2020 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock additional aggregate number of shares reserved		1,048,963
Common stock shares reserved for future issuance	433,515
2020 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares reserved for future issuance	210,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense Recognized for Options and RSUs Granted (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,431	$ 561	$ 3,872	$ 1,001
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	321	105	912	245
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,110	$ 456	$ 2,960	$ 756

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Provision or benefit for income taxes	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jul. 31, 2019	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Cumulative dividends on convertible preferred stock		$ 2,396		$ 7,189
Series C Convertible Preferred Stock | Maximum
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Additional convertible preferred stock could have been issued	17,014,902		17,014,902

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stock Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	3,815,682	2,615,892
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	984,700	80,000
Warrants to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from calculation of diluted net loss per share	27,759	27,759